US Patent Issued to SUNSHINE LAKE PHARMA on March 31 for "FGF21 variant polypeptide molecules and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,132, issued on March 31, was assigned to SUNSHINE LAKE PHARMA Co. LTD. (Dongguan, China).

"FGF21 variant polypeptide molecules and application thereof" was invented by Chao Chen (Dongguan, China), Shushan Lin (Dongguan, China), Yu Li (Dongguan, China), Xiaoping Li (Dongguan, China), Xiaofeng Chen (Dongguan, China), Wenjia Li (Dongguan, China), Liang Liu (Dongguan, China) and Zheng Fu (Dongguan, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities...